{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T18:13:02Z","timestamp":1789841582826,"version":"4.0.1"},"reference-count":20,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"28","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2020,10,1]]},"abstract":"<jats:sec><jats:title>PURPOSE<\/jats:title><jats:p> In advanced gastrointestinal stromal tumor (GIST), there is an unmet need for therapies that target both primary and secondary mutations of pathogenic KIT\/PDGFRA oncoproteins. Ripretinib is a novel switch-control kinase inhibitor designed to inhibit a wide range of KIT and PDGFRA mutations. <\/jats:p><\/jats:sec><jats:sec><jats:title>PATIENTS AND METHODS<\/jats:title><jats:p> This first-in-human, to our knowledge, phase I study of ripretinib (ClinicalTrials.gov identifier: NCT02571036) included a dose-escalation phase and subsequent expansion phase at the recommended phase II dose (RP2D). Eligible patients included those with advanced GIST, intolerant to or experienced progression on \u2265 1 line of systemic therapy, and other advanced malignancies. Safety, dose-limiting toxicities (DLTs), maximum-tolerated dose (MTD), and preliminary antitumor activity were evaluated. <\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p> At data cutoff (August 31, 2019), 258 patients (n = 184 GIST) were enrolled, with 68 patients in the dose-escalation phase. Three DLTs were reported: grade 3 lipase increase (n = 2; 100 mg and 200 mg twice a day) and grade 4 increased creatine phosphokinase (n = 1; 150 mg once daily). MTD was not reached (maximum dose evaluated, 200 mg twice a day); 150 mg once daily was established as the RP2D. The most frequent (&gt; 30%) treatment-emergent adverse events in patients with GIST receiving ripretinib 150 mg once daily (n = 142) were alopecia (n = 88 [62.0%]), fatigue (n = 78 [54.9%]), myalgia (n = 69 [48.6%]), nausea (n = 65 [45.8%]), palmar-plantar erythrodysesthesia (n = 62 [43.7%]), constipation (n = 56 [39.4%]), decreased appetite (n = 48 [33.8%]), and diarrhea (n = 47 [33.1%]). Objective response rate (confirmed) of 11.3% (n = 16\/142) ranging from 7.2% (n = 6\/83; fourth line or greater) to 19.4% (n = 6\/31; second line) and median progression-free survival ranging from 5.5 months (fourth line or greater) to 10.7 months (second line), on the basis of investigator assessment, were observed. <\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p> Ripretinib is a well-tolerated, novel inhibitor of KIT and PDGFRA mutant kinases with promising activity in patients with refractory advanced GIST. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.20.00522","type":"journal-article","created":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T19:59:26Z","timestamp":1597694366000},"page":"3294-3303","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":81,"title":["Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib"],"prefix":"10.1200","volume":"38","author":[{"given":"Filip","family":"Janku","sequence":"first","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albiruni R.","family":"Abdul Razak","sequence":"additional","affiliation":[{"name":"Toronto Sarcoma Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Chi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY and Department of Medicine, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Heinrich","sequence":"additional","affiliation":[{"name":"Department of Medicine, Portland VA Health Care System and OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"von Mehren","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin L.","family":"Jones","sequence":"additional","affiliation":[{"name":"Sarcoma Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Ganjoo","sequence":"additional","affiliation":[{"name":"Department of Oncology, Stanford University Medical Center, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Trent","sequence":"additional","affiliation":[{"name":"Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Gelderblom","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeta","family":"Somaiah","sequence":"additional","affiliation":[{"name":"Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simin","family":"Hu","sequence":"additional","affiliation":[{"name":"Deciphera Pharmaceuticals, LLC, Waltham, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Rosen","sequence":"additional","affiliation":[{"name":"Deciphera Pharmaceuticals, LLC, Waltham, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Su","sequence":"additional","affiliation":[{"name":"Deciphera Pharmaceuticals, LLC, Waltham, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Ruiz-Soto","sequence":"additional","affiliation":[{"name":"Deciphera Pharmaceuticals, LLC, Waltham, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gordon","sequence":"additional","affiliation":[{"name":"HonorHealth Research Institute, Scottsdale, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"George","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/path.2382"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.190"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-015545"},{"key":"B4","first-page":"3213","volume":"52","author":"Hermanson M","year":"1992","journal-title":"Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.0228"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.4403"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)17098-0"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69446-4"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61857-1"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.7461"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1211"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1186\/s13569-019-0112-7"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy309"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0487-5"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.14.068"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.04.006"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.01.011"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41536-017-0013-4"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30168-6"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0633"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.20.00522","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T07:10:40Z","timestamp":1653808240000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.20.00522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,1]]},"references-count":20,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2020,10,1]]}},"alternative-id":["10.1200\/JCO.20.00522"],"URL":"https:\/\/doi.org\/10.1200\/jco.20.00522","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,1]]},"assertion":[{"value":"2020-06-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}